

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): **February 27, 2017**

BIONIK LABORATORIES CORP.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of
Incorporation or Organization)

000-54717

(Commission File Number)

27-1340346

(IRS Employer Identification No.)

483 Bay Street, N105
Toronto, ON

(Address of Principal Executive Offices)

M5G 2C9

(Zip Code)

Registrant's Telephone Number, Including Area Code: (416) 640-7887

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry Into a Material Definitive Agreement

On February 27, 2017, Bionik Laboratories Corp. (the “Registrant”) entered into Allonge #3 to Secured Promissory Note (the “Allonge”), with Park Hill Capital Inc., pursuant to which the maturity date of the secured promissory note referred to in the Allonge was extended until July 1, 2017.

The foregoing description of the Allonge is not complete and is subject to and qualified in its entirety by reference to the Allonge, a copy of which is attached as Exhibit 10.1 to this Form 8-K, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

| Exhibit No. | Description |
|--------------------|---------------------------------------|
| 10.1 | Allonge #3 to Secured Promissory Note |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: March 1, 2017

BIONIK LABORATORIES CORP.

By: /s/ Leslie Markow

Name: Leslie Markow

Title: Chief Financial Officer

ALLONGE #3 TO SECURED PROMISSORY NOTE

Allonge #3 to that certain Secured Promissory Note attached hereto as Exhibit 1 and made a part hereof in the principal amount of \$200,000.00 dated February 20, 2014, from Interactive Motion Technologies, Inc. (now known as Bionik, Inc.), as Maker, to the order of Park Hill Capital Inc., as Holder (“Allonge”).

Borrower and Lender agree that the Secured Promissory Note, as amended pursuant to that Allonge to Secured Promissory Note dated February 22, 2016 and Allonge #2 to Secured Promissory Note dated August 12, 2016, shall be revised as follows:

- 1. Section 1 of the Secured Promissory Note shall be amended to read as follows:

“1. Maturity. The Loan Amount shall be due and payable on July 1, 2017. All payments shall be applied first to accrued but unpaid interest and thereafter to principal.”

This Allonge is intended to be attached to and made a permanent part of the Secured Promissory Note.

Dated this 27th day of February, 2017.

Maker:

BIONIK, INC.

By: /s/ Leslie Markow

Name: Leslie Markow

Title:

Holder:

PARK HILL CAPITAL INC.

By: /s/ Thomas Ueki

Name: Thomas Ueki

Title: Director
